top of page

Global Regulatory Toxicology Consulting

Let's chat about your project

Search

AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data

jeanfrancoismaison
Apr 22
1 min read

https://www.biospace.com/drug-development/astrazeneca-daiichi-sankyo-push-enhertu-to-frontline-breast-cancer-with-phase-iii-data?utm_campaign=Newsletter%20%7C%20GenePool&utm_medium=email&_hsenc=p2ANqtz-94PN3WAWgnJq-r7F5oA10ry7XFGijmEZCoQSaww7gE0SRRMcd_46buDhigBVJUFBRWItgsJCtsbGWdgowath3yzfv68cBe4yPCqCdPmSGLOUbDlow&_hsmi=357834653&utm_content=357834653&utm_source=hs_email

Recent Posts

ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis

https://pubmed.ncbi.nlm.nih.gov/40467521/

Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activity

https://pubmed.ncbi.nlm.nih.gov/40450523/

MDM2 inhibitors in sarcomas: results and next steps

https://pubmed.ncbi.nlm.nih.gov/40464483/

bottom of page